Bliss GVS Pharma Ltd (BLISSGVS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 730684,
    "name": "Bliss GVS Pharma",
    "stock_name": "Bliss GVS Pharma",
    "full_name": "Bliss GVS Pharma Ltd",
    "name_url": "stocks-analysis/bliss-gvs-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "179.45",
    "chg": 6.15,
    "chgp": "3.55%",
    "dir": 1,
    "prev_price": "173.30",
    "mcapval": "1,899.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506197,
    "symbol": "BLISSGVS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE416D01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "18.94 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/bliss-gvs-pharma-730684-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-hits-intraday-high-with-749-surge-on-4-dec-2025-3746739",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BlissGVSPharma_priceRelatedfactors_3746739.png",
        "date": "2025-12-04 12:11:24",
        "description": "Bliss GVS Pharma demonstrated robust intraday performance on 4 December 2025, surging to an intraday high of Rs 166.8, reflecting a 7.68% rise during the trading session. The stock outpaced its sector and broader market indices, supported by notable volatility and sustained buying interest throughout the day."
      },
      {
        "title": "Is Bliss GVS Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bliss-gvs-pharma-overvalued-or-undervalued-3739854",
        "imagepath": "",
        "date": "2025-12-02 08:14:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Attractiveness</strong></p>\n<p>Bliss GVS Pharma’s current price-to-earnings (PE) ratio stands at 15.00, which is notably lower than several major competitors in the pharmaceutical sector. For instance, industry giants such as Sun Pharma and Divi’s Laboratories trade at PE ratios exceeding 35 and 60 respectively, reflecting their premium valuations. The company’s price-to-book value of 1.45 also suggests a reasonable valuation relative to its net asset base, avoiding the extremes of overvaluation often seen in high-growth pharma stocks.</p>\n<p>Further supporting the attractive valuation thesis is the enterprise value to EBITDA (EV/EBITDA) ratio of 12.07, which is below the levels observed in many peers. This metric indicates that the market is pricing Bliss GVS Phar..."
      },
      {
        "title": "Bliss GVS Pharma Technical Momentum Shifts Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-technical-momentum-shifts-amid-mixed-market-signals-3740206",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BlissGVSPharma_technicaldot_3740206.png",
        "date": "2025-12-02 08:08:10",
        "description": "Bliss GVS Pharma has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The pharmaceutical company’s stock price currently trades at ₹155.55, down from the previous close of ₹166.25, amid a broader market environment that has seen mixed returns compared to the Sensex benchmark."
      },
      {
        "title": "Why is Bliss GVS Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bliss-gvs-pharma-fallingrising-3739528",
        "imagepath": "",
        "date": "2025-12-02 00:33:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Stock Performance Against Benchmarks</strong></p>\n<p>Bliss GVS Pharma’s recent price movement contrasts sharply with the broader market’s positive trajectory. Over the past week, the stock declined by 8.26%, while the Sensex gained 0.87%. This divergence highlights the stock’s relative weakness amid a generally buoyant market environment. Similarly, on a one-month basis, the stock marginally fell by 0.67%, whereas the Sensex advanced by 2.03%. Year-to-date, the stock is down 5.53%, in stark contrast to the Sensex’s 9.60% gain. Even over a one-year horizon, Bliss GVS Pharma’s shares have declined by 2.78%, while the benchmark index rose by 7.32%. These figures underscore the stock’s persistent underperformance compared to the broader market indices.</p>\n<p><strong>Intraday Trading and Volume ..."
      },
      {
        "title": "Bliss GVS Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bliss-gvs-pharma-upgraded-to-hold-by-marketsmojo-on-12-nov-2025-3736966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_mojoScore_3736966.png",
        "date": "2025-11-29 17:52:00",
        "description": "Bliss GVS Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of stable quality metrics, fair valuation, and bullish technical indicators, set against a backdrop of flat financial trends and modest market returns."
      },
      {
        "title": "Bliss GVS Pharma Shows Shift in Price Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-technical-momentum-shifts-signal-bullish-outlook-3727547",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_technicaldot_3727547.png",
        "date": "2025-11-25 08:09:12",
        "description": "Bliss GVS Pharma has exhibited a notable shift in its price momentum, reflecting a transition in technical parameters that suggest evolving market sentiment. Recent trading activity and technical indicators reveal a complex picture for this Pharmaceuticals & Biotechnology stock, with bullish trends emerging alongside some cautionary signals."
      },
      {
        "title": "Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-hits-intraday-high-with-723-surge-on-24-nov-2025-3725680",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_priceRelatedfactors_3725680.png",
        "date": "2025-11-24 14:02:15",
        "description": "Bliss GVS Pharma demonstrated robust intraday performance on 24 Nov 2025, reaching a day’s high of Rs 171.3, reflecting a gain of 7.16% amid a broadly positive market environment."
      },
      {
        "title": "Is Bliss GVS Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bliss-gvs-pharma-overvalued-or-undervalued-3716745",
        "imagepath": "",
        "date": "2025-11-20 08:06:21",
        "description": "As of 19 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a PE ratio of 15.51, an EV to EBITDA of 12.52, and a PEG ratio of 0.88, all of which suggest that it is trading at a discount compared to its peers.\n\nIn comparison to its industry peers, Bliss GVS Pharma's valuation metrics stand out positively. For instance, Sun Pharma has a significantly higher PE ratio of 37.07, while Divi's Lab is even more expensive at 68.85. Additionally, Cipla and Dr. Reddy's Labs, both classified as attractive, have PE ratios of 22.64 and 18.06, respectively. Despite a recent underperformance relative to the Sensex on a year-to-date basis, Bliss GVS Pharma has shown strong returns over the past year, outperforming the index with a return of 33.10% compared to 9.81% for the Se..."
      },
      {
        "title": "Is Bliss GVS Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bliss-gvs-pharma-overvalued-or-undervalued-3713602",
        "imagepath": "",
        "date": "2025-11-19 08:09:08",
        "description": "As of 18 November 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 16.15, an EV to EBITDA of 13.09, and a PEG Ratio of 0.91, which suggest that the stock is reasonably priced relative to its earnings growth potential.\n\nIn comparison to its peers, Bliss GVS Pharma's valuation stands out against companies such as Sun Pharma, which is considered expensive with a PE Ratio of 36.56, and Cipla, which is rated attractive with a PE Ratio of 22.49. The recent stock performance of Bliss GVS Pharma has outpaced the Sensex, with a 1-year return of 38.54% compared to the Sensex's 9.48%, reinforcing its competitive position in the market...."
      }
    ],
    "total": 269,
    "sid": "730684",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/bliss-gvs-pharma-730684"
  },
  "announcements": [
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "30-Jan-2026",
      "details": "Please find enclosed herewith the Voting Result alongwith the Scrutinizer Report.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "30-Jan-2026",
      "details": "Please find enclosed herewith the Scrutinizer Report alongwith the Voting Results.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "27-Jan-2026",
      "details": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 we would like to inform you that Bliss GVS International PTE Ltd. Singapore a wholly owned subsidiary of Bliss GVS Pharma Limited has incorporated a wholly-owned subsidiary namely Theralife Pharma RDC Private Limited Kinshasa Gombe Democratic Republic of the Congo.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has declared <strong>50%</strong> dividend, ex-date: 24 Jul 25",
          "dt": "2025-07-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>3:5</strong> bonus issue, ex-date: 26 Sep 08",
          "dt": "2008-09-26",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum

2025-12-04 12:11:24

Bliss GVS Pharma demonstrated robust intraday performance on 4 December 2025, surging to an intraday high of Rs 166.8, reflecting a 7.68% rise during the trading session. The stock outpaced its sector and broader market indices, supported by notable volatility and sustained buying interest throughout the day.

Is Bliss GVS Pharma overvalued or undervalued?

2025-12-02 08:14:34

Valuation Metrics Indicate Attractiveness Bliss GVS Pharma’s current price-to-earnings (PE) ratio stands at 15.00, which is notably lower than several major competitors in the pharmaceutical sector. For instance, industry giants such as Sun Pharma and Divi’s Laboratories trade at PE ratios exceeding 35 and 60 respectively, reflecting their premium valuations. The company’s price-to-book value of 1.45 also suggests a reasonable valuation relative to its net asset base, avoiding the extremes of overvaluation often seen in high-growth pharma stocks. Further supporting the attractive valuation thesis is the enterprise value to EBITDA (EV/EBITDA) ratio of 12.07, which is below the levels observed in many peers. This metric indicates that the market is pricing Bliss GVS Phar...

Bliss GVS Pharma Technical Momentum Shifts Amid Market Volatility

2025-12-02 08:08:10

Bliss GVS Pharma has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The pharmaceutical company’s stock price currently trades at ₹155.55, down from the previous close of ₹166.25, amid a broader market environment that has seen mixed returns compared to the Sensex benchmark.

Why is Bliss GVS Pharma falling/rising?

2025-12-02 00:33:44

Stock Performance Against Benchmarks Bliss GVS Pharma’s recent price movement contrasts sharply with the broader market’s positive trajectory. Over the past week, the stock declined by 8.26%, while the Sensex gained 0.87%. This divergence highlights the stock’s relative weakness amid a generally buoyant market environment. Similarly, on a one-month basis, the stock marginally fell by 0.67%, whereas the Sensex advanced by 2.03%. Year-to-date, the stock is down 5.53%, in stark contrast to the Sensex’s 9.60% gain. Even over a one-year horizon, Bliss GVS Pharma’s shares have declined by 2.78%, while the benchmark index rose by 7.32%. These figures underscore the stock’s persistent underperformance compared to the broader market indices. Intraday Trading and Volume ...

Bliss GVS Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-29 17:52:00

Bliss GVS Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of stable quality metrics, fair valuation, and bullish technical indicators, set against a backdrop of flat financial trends and modest market returns.

Bliss GVS Pharma Shows Shift in Price Momentum Amid Mixed Technical Signals

2025-11-25 08:09:12

Bliss GVS Pharma has exhibited a notable shift in its price momentum, reflecting a transition in technical parameters that suggest evolving market sentiment. Recent trading activity and technical indicators reveal a complex picture for this Pharmaceuticals & Biotechnology stock, with bullish trends emerging alongside some cautionary signals.

Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum

2025-11-24 14:02:15

Bliss GVS Pharma demonstrated robust intraday performance on 24 Nov 2025, reaching a day’s high of Rs 171.3, reflecting a gain of 7.16% amid a broadly positive market environment.

Is Bliss GVS Pharma overvalued or undervalued?

2025-11-20 08:06:21

As of 19 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a PE ratio of 15.51, an EV to EBITDA of 12.52, and a PEG ratio of 0.88, all of which suggest that it is trading at a discount compared to its peers. In comparison to its industry peers, Bliss GVS Pharma's valuation metrics stand out positively. For instance, Sun Pharma has a significantly higher PE ratio of 37.07, while Divi's Lab is even more expensive at 68.85. Additionally, Cipla and Dr. Reddy's Labs, both classified as attractive, have PE ratios of 22.64 and 18.06, respectively. Despite a recent underperformance relative to the Sensex on a year-to-date basis, Bliss GVS Pharma has shown strong returns over the past year, outperforming the index with a return of 33.10% compared to 9.81% for the Se...

Is Bliss GVS Pharma overvalued or undervalued?

2025-11-19 08:09:08

As of 18 November 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 16.15, an EV to EBITDA of 13.09, and a PEG Ratio of 0.91, which suggest that the stock is reasonably priced relative to its earnings growth potential. In comparison to its peers, Bliss GVS Pharma's valuation stands out against companies such as Sun Pharma, which is considered expensive with a PE Ratio of 36.56, and Cipla, which is rated attractive with a PE Ratio of 22.49. The recent stock performance of Bliss GVS Pharma has outpaced the Sensex, with a 1-year return of 38.54% compared to the Sensex's 9.48%, reinforcing its competitive position in the market....

View All News